Literature DB >> 1343695

Antibodies in falciparum malaria: what matters most, quantity or quality?

H Bouharoun-Tayoun1, P Druilhe.   

Abstract

In view of the recent demonstration that antibodies that are protective against Plasmodium falciparum malaria may act in collaboration with blood monocytes, we have investigated the isotype content of sera from individuals with defined clinical states of resistance or susceptibility to malaria. Profound differences in the distribution of each Ig subclass and particularly in the ratio of cytophilic versus noncytophilic antibodies were found. In protected subjects, two cytophilic isotypes, IgG1 and IgG3 were found to predominate. In non-protected subjects, i.e. children and primary attack adults, three different situations were encountered: a) an imbalance in which IgG2, a non-cytophilic class, predominated (mostly seen in primary attacks); b) an imbalance in which mostly IgM antibodies predominated (a frequent event in children) or c) less frequently, an overall low level of antimalarial antibodies. Of 33 non immune subjects studied all, except one, had one of the above defects. The function of total Ig presenting such an isotype imbalance was studied in vitro in Antibody-Dependent-Cellular-Inhibition assays. Not only did IgG from protected subjects cooperate efficiently with blood monocytes, whilst IgG from non-protected groups did not, but moreover the latter inhibit the in vitro effect of the former: in competition assays whole IgG from primary attack cases with increased IgG2 content, competed with IgG from immune adults, thus suggesting that non-protected subjects had antibodies to epitopes critical for protection, but that these antibodies are non functional.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1343695     DOI: 10.1590/s0074-02761992000700038

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  20 in total

1.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

3.  Genome-wide significant linkage to IgG subclass responses against Plasmodium falciparum antigens on chromosomes 8p22-p21, 9q34 and 20q13.

Authors:  A Brisebarre; B Kumulungui; S Sawadogo; S Afridi; F Fumoux; P Rihet
Journal:  Genes Immun       Date:  2014-12-18       Impact factor: 2.676

4.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

6.  Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Authors:  Issa Nebie; Amidou Diarra; Alphonse Ouedraogo; Issiaka Soulama; Edith C Bougouma; Alfred B Tiono; Amadou T Konate; Roma Chilengi; Michael Theisen; Daniel Dodoo; Ed Remarque; Samuel Bosomprah; Paul Milligan; Sodiomon B Sirima
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

7.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models.

Authors:  Lena-Juliette Daher; Corine G Demanga; Eric Prieur; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-07-06       Impact factor: 3.441

8.  Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.

Authors:  John P A Lusingu; Samwel Gesase; Salum Msham; Filbert Francis; Martha Lemnge; Misago Seth; Samwel Sembuche; Acleus Rutta; Daniel Minja; Method D Segeja; Samuel Bosomprah; Simon Cousens; Ramadhani Noor; Roma Chilengi; Pierre Druilhe
Journal:  Malar J       Date:  2009-07-17       Impact factor: 2.979

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

Review 10.  Experience and challenges from clinical trials with malaria vaccines in Africa.

Authors:  Grace Mwangoka; Bernhards Ogutu; Beverly Msambichaka; Tutu Mzee; Nahya Salim; Shubis Kafuruki; Maxmillian Mpina; Seif Shekalaghe; Marcel Tanner; Salim Abdulla
Journal:  Malar J       Date:  2013-03-04       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.